Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.


FDA Panel Endorses Early Trials of Promising Anticancer Agents in Pediatric Patients

June 29th 2016

Members of the Pediatric Subcommittee of the FDA's Oncologic Drugs Advisory Committee voiced their support for new clinical trials examining promising cancer agents in pediatric patients.

A Look to the Future in RCC

June 29th 2016

A Changing Landscape in RCC

June 29th 2016

Novel Approaches in Advanced RCC

June 29th 2016

Long-Term RCC Data with Nivolumab

June 29th 2016

Second and Third-Line Decisions in RCC

June 29th 2016

The Role of Lenvatinib in Advanced RCC

June 29th 2016

Options in the Third Line Setting for RCC

June 29th 2016

The Rationale for Cabozantinib in Advanced RCC

June 29th 2016

Patient Selection and Checkpoint Inhibition in RCC

June 29th 2016

Advanced RCC Sequencing Challenges

June 29th 2016

Assessing Treatment Response with RCC First-Line Therapies

June 29th 2016

RCC First-Line Toxicity Considerations

June 29th 2016

Choosing Among TKIs in Advanced RCC

June 29th 2016

Determining Initial Therapeutic Approach in Advanced RCC

June 29th 2016

Goals of Therapy in Advanced RCC

June 29th 2016

When to Start Systemic Treatment in Newly Diagnosed RCC

June 29th 2016

FDA Grants Lutathera Priority Review for Neuroendocrine Tumors

June 27th 2016

The FDA has granted a priority review designation to Lutathera (177Lutetium DOTA-octreotate) as a treatment for patients with gastroenteropancreatic neuroendocrine tumors.

HHS Rejects Bid to Broaden Access to Enzalutamide

June 23rd 2016

The Department of Health and Human Services has turned down a request to override the patent for prostate cancer drug enzalutamide (Xtandi) so that it can be sold to a broader base of patients at a reduced price.

Finding Time for Stress Relief Increasingly Difficult for Oncologists

June 15th 2016

Many doctors in oncology are pushing themselves to the extreme, and longer workdays have become a fact of life.